Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 82

1.

High-Throughput Label-Free Isolation of Heterogeneous Circulating Tumor Cells and CTC Clusters from Non-Small-Cell Lung Cancer Patients.

Zeinali M, Lee M, Nadhan A, Mathur A, Hedman C, Lin E, Harouaka R, Wicha MS, Zhao L, Palanisamy N, Hafner M, Reddy R, Kalemkerian GP, Schneider BJ, Hassan KA, Ramnath N, Nagrath S.

Cancers (Basel). 2020 Jan 3;12(1). pii: E127. doi: 10.3390/cancers12010127.

PMID:
31947893
2.

A Pilot Study of Atezolizumab plus Hypofractionated Image-guided Radiotherapy for the Treatment of Advanced Non-Small Cell Lung Cancer.

Qin A, Rengan R, Lee S, Santana-Davila R, Goulart BHL, Martins R, Baik C, Kalemkerian GP, Hassan KA, Schneider BJ, Hayman JA, Jolly S, Hearn J, Lawrence TS, Towlerton AMH, Tewari M, Thomas D, Zhao L, Brown N, Frankel TL, Warren EH, Ramnath N.

Int J Radiat Oncol Biol Phys. 2019 Nov 19. pii: S0360-3016(19)34007-6. doi: 10.1016/j.ijrobp.2019.10.047. [Epub ahead of print]

PMID:
31756415
3.

Validation of a serum 4-microRNA signature for the detection of lung cancer.

Yang X, Su W, Chen X, Geng Q, Zhai J, Shan H, Guo C, Wang Z, Fu H, Jiang H, Lin J, Lagisetty KH, Zhang J, Li Y, Yang S, Massion PP, Beer DG, Chang AC, Ramnath N, Chen G.

Transl Lung Cancer Res. 2019 Oct;8(5):636-648. doi: 10.21037/tlcr.2019.09.11.

4.

Isolation and Profiling of Circulating Tumor-Associated Exosomes Using Extracellular Vesicular Lipid-Protein Binding Affinity Based Microfluidic Device.

Kang YT, Purcell E, Palacios-Rolston C, Lo TW, Ramnath N, Jolly S, Nagrath S.

Small. 2019 Nov;15(47):e1903600. doi: 10.1002/smll.201903600. Epub 2019 Oct 7.

PMID:
31588683
5.

Reactive Oxygen Species in the Tumor Microenvironment: An Overview.

Weinberg F, Ramnath N, Nagrath D.

Cancers (Basel). 2019 Aug 16;11(8). pii: E1191. doi: 10.3390/cancers11081191. Review.

6.

Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy.

Zhang Q, Green MD, Lang X, Lazarus J, Parsels JD, Wei S, Parsels LA, Shi J, Ramnath N, Wahl DR, Pasca di Magliano M, Frankel TL, Kryczek I, Lei YL, Lawrence TS, Zou W, Morgan MA.

Cancer Res. 2019 Aug 1;79(15):3940-3951. doi: 10.1158/0008-5472.CAN-19-0761. Epub 2019 May 17.

PMID:
31101760
7.

PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer.

Wang Y, Kim TH, Fouladdel S, Zhang Z, Soni P, Qin A, Zhao L, Azizi E, Lawrence TS, Ramnath N, Cuneo KC, Nagrath S.

Sci Rep. 2019 Jan 24;9(1):566. doi: 10.1038/s41598-018-36096-7.

8.

Targeting IL22: a potential therapeutic approach for Kras mutant lung cancer?

Weinberg FD, Ramnath N.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S243-S247. doi: 10.21037/tlcr.2018.09.04. No abstract available.

9.

Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy.

Hovelson DH, Liu CJ, Wang Y, Kang Q, Henderson J, Gursky A, Brockman S, Ramnath N, Krauss JC, Talpaz M, Kandarpa M, Chugh R, Tuck M, Herman K, Grasso CS, Quist MJ, Feng FY, Haakenson C, Langmore J, Kamberov E, Tesmer T, Husain H, Lonigro RJ, Robinson D, Smith DC, Alva AS, Hussain MH, Chinnaiyan AM, Tewari M, Mills RE, Morgan TM, Tomlins SA.

Oncotarget. 2017 Sep 22;8(52):89848-89866. doi: 10.18632/oncotarget.21163. eCollection 2017 Oct 27.

10.

The "liquid biopsy" in non-small cell lung cancer - not quite ready for prime time use.

Qin A, Ramnath N.

Transl Cancer Res. 2016 Oct;5(Suppl 4):S632-S635. doi: 10.21037/tcr.2016.10.29. No abstract available.

11.

Radiation-induced lung toxicity in non-small-cell lung cancer: Understanding the interactions of clinical factors and cytokines with the dose-toxicity relationship.

Hawkins PG, Boonstra PS, Hobson ST, Hearn JWD, Hayman JA, Ten Haken RK, Matuszak MM, Stanton P, Kalemkerian GP, Ramnath N, Lawrence TS, Schipper MJ, Spring Kong FM, Jolly S.

Radiother Oncol. 2017 Oct;125(1):66-72. doi: 10.1016/j.radonc.2017.09.005. Epub 2017 Sep 23.

12.

Integrative clinical genomics of metastatic cancer.

Robinson DR, Wu YM, Lonigro RJ, Vats P, Cobain E, Everett J, Cao X, Rabban E, Kumar-Sinha C, Raymond V, Schuetze S, Alva A, Siddiqui J, Chugh R, Worden F, Zalupski MM, Innis J, Mody RJ, Tomlins SA, Lucas D, Baker LH, Ramnath N, Schott AF, Hayes DF, Vijai J, Offit K, Stoffel EM, Roberts JS, Smith DC, Kunju LP, Talpaz M, CieĊ›lik M, Chinnaiyan AM.

Nature. 2017 Aug 17;548(7667):297-303. doi: 10.1038/nature23306. Epub 2017 Aug 2.

13.

Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early-Stage Lung Cancers.

Murlidhar V, Reddy RM, Fouladdel S, Zhao L, Ishikawa MK, Grabauskiene S, Zhang Z, Lin J, Chang AC, Carrott P, Lynch WR, Orringer MB, Kumar-Sinha C, Palanisamy N, Beer DG, Wicha MS, Ramnath N, Azizi E, Nagrath S.

Cancer Res. 2017 Sep 15;77(18):5194-5206. doi: 10.1158/0008-5472.CAN-16-2072. Epub 2017 Jul 17.

14.

Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial.

Kong FM, Ten Haken RK, Schipper M, Frey KA, Hayman J, Gross M, Ramnath N, Hassan KA, Matuszak M, Ritter T, Bi N, Wang W, Orringer M, Cease KB, Lawrence TS, Kalemkerian GP.

JAMA Oncol. 2017 Oct 1;3(10):1358-1365. doi: 10.1001/jamaoncol.2017.0982.

15.

Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer.

Qin A, Street L, Cease K, Viglianti BL, Warren EH, Zhao L, Ramnath N.

Clin Lung Cancer. 2017 Sep;18(5):559-564. doi: 10.1016/j.cllc.2017.01.012. Epub 2017 Feb 9.

16.

Oncogenic Potential of CYP24A1 in Lung Adenocarcinoma.

Shiratsuchi H, Wang Z, Chen G, Ray P, Lin J, Zhang Z, Zhao L, Beer D, Ray D, Ramnath N.

J Thorac Oncol. 2017 Feb;12(2):269-280. doi: 10.1016/j.jtho.2016.10.010. Epub 2016 Oct 26.

17.

Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study.

Zhang Z, Shiratsuchi H, Palanisamy N, Nagrath S, Ramnath N.

J Thorac Oncol. 2017 Feb;12(2):397-402. doi: 10.1016/j.jtho.2016.07.027. Epub 2016 Aug 6.

18.

Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer.

Qin A, Coffey DG, Warren EH, Ramnath N.

Cancer Med. 2016 Sep;5(9):2567-78. doi: 10.1002/cam4.819. Epub 2016 Jul 15. Review.

19.

Optimizing the Detection of Circulating Markers to Aid in Early Lung Cancer Detection.

Murlidhar V, Ramnath N, Nagrath S, Reddy RM.

Cancers (Basel). 2016 Jun 28;8(7). pii: E61. doi: 10.3390/cancers8070061. Review.

20.

Impact of Staging With Positron-emission Tomography (PET) and Comorbidities on Management and Survival of American Veterans With Stage I-III Non-Small Cell Lung Cancer.

Raghunathan R, Cease K, Troeschel S, Zhao L, Gross M, Chen G, Chopra V, Ramnath N.

Am J Clin Oncol. 2018 May;41(5):513-518. doi: 10.1097/COC.0000000000000316.

PMID:
27322696

Supplemental Content

Loading ...
Support Center